Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Legends of allergy/immunology: Georges Köhler and the discovery of MONOCLONAL antibodies.

Alkan SS.

Allergy. 2019 Jul;74(7):1412-1414. doi: 10.1111/all.13798. Epub 2019 Apr 29. No abstract available.

PMID:
30920663
2.

Suppression of B-cell activation and IgE, IgA, IgG1 and IgG4 production by mammalian telomeric oligonucleotides.

Sackesen C, van de Veen W, Akdis M, Soyer O, Zumkehr J, Ruckert B, Stanic B, Kalaycı O, Alkan SS, Gursel I, Akdis CA.

Allergy. 2013;68(5):593-603. doi: 10.1111/all.12133. Epub 2013 Mar 9.

PMID:
23480796
3.

Vaccines - the key paradigm for the 21st century's health care strategy: 5th Semmering vaccine symposium, Baden/Vienna. Editorial.

Alkan SS, Decker T, von Gabain A.

Vaccine. 2012 Jun 19;30(29):4299-300. doi: 10.1016/j.vaccine.2012.03.077. Epub 2012 Mar 30. No abstract available.

PMID:
22464968
4.

Larazotide acetate promotes tight junction assembly in epithelial cells.

Gopalakrishnan S, Tripathi A, Tamiz AP, Alkan SS, Pandey NB.

Peptides. 2012 May;35(1):95-101. doi: 10.1016/j.peptides.2012.02.016. Epub 2012 Feb 28.

PMID:
22401910
5.

Larazotide acetate regulates epithelial tight junctions in vitro and in vivo.

Gopalakrishnan S, Durai M, Kitchens K, Tamiz AP, Somerville R, Ginski M, Paterson BM, Murray JA, Verdu EF, Alkan SS, Pandey NB.

Peptides. 2012 May;35(1):86-94. doi: 10.1016/j.peptides.2012.02.015. Epub 2012 Feb 27.

PMID:
22401908
6.

Phosphorothioate 2' deoxyribose oligomers as microbicides that inhibit human immunodeficiency virus type 1 (HIV-1) infection and block Toll-like receptor 7 (TLR7) and TLR9 triggering by HIV-1.

Fraietta JA, Mueller YM, Do DH, Holmes VM, Howett MK, Lewis MG, Boesteanu AC, Alkan SS, Katsikis PD.

Antimicrob Agents Chemother. 2010 Oct;54(10):4064-73. doi: 10.1128/AAC.00367-10. Epub 2010 Jul 12.

7.

Mechanism of action of ZOT-derived peptide AT-1002, a tight junction regulator and absorption enhancer.

Gopalakrishnan S, Pandey N, Tamiz AP, Vere J, Carrasco R, Somerville R, Tripathi A, Ginski M, Paterson BM, Alkan SS.

Int J Pharm. 2009 Jan 5;365(1-2):121-30. doi: 10.1016/j.ijpharm.2008.08.047. Epub 2008 Sep 11.

PMID:
18832018
8.

Structure-activity relationship studies of permeability modulating peptide AT-1002.

Li M, Oliver E, Kitchens KM, Vere J, Alkan SS, Tamiz AP.

Bioorg Med Chem Lett. 2008 Aug 15;18(16):4584-6. doi: 10.1016/j.bmcl.2008.07.028. Epub 2008 Jul 15.

PMID:
18667315
9.

Comparison of human B cell activation by TLR7 and TLR9 agonists.

Hanten JA, Vasilakos JP, Riter CL, Neys L, Lipson KE, Alkan SS, Birmachu W.

BMC Immunol. 2008 Jul 24;9:39. doi: 10.1186/1471-2172-9-39.

10.

TLR7 agonist 852A inhibition of tumor cell proliferation is dependent on plasmacytoid dendritic cells and type I IFN.

Inglefield JR, Dumitru CD, Alkan SS, Gibson SJ, Lipson KE, Tomai MA, Larson CJ, Vasilakos JP.

J Interferon Cytokine Res. 2008 Apr;28(4):253-63. doi: 10.1089/jir.2007.0097.

PMID:
18439103
11.

Inhibition of in vitro tumor cell proliferation by cytokines induced by combinations of TLR or TLR and TCR agonists.

Ghosh TK, Mickelson DJ, Lipson KE, Alkan SS.

Int Immunopharmacol. 2007 Nov;7(11):1471-82. Epub 2007 Jun 26.

PMID:
17761351
12.

TLR-TLR cross talk in human PBMC resulting in synergistic and antagonistic regulation of type-1 and 2 interferons, IL-12 and TNF-alpha.

Ghosh TK, Mickelson DJ, Solberg JC, Lipson KE, Inglefield JR, Alkan SS.

Int Immunopharmacol. 2007 Aug;7(8):1111-21. Epub 2007 May 4.

PMID:
17570328
13.

Toll-like receptor (TLR) 2-9 agonists-induced cytokines and chemokines: I. Comparison with T cell receptor-induced responses.

Ghosh TK, Mickelson DJ, Fink J, Solberg JC, Inglefield JR, Hook D, Gupta SK, Gibson S, Alkan SS.

Cell Immunol. 2006 Sep;243(1):48-57. Epub 2007 Jan 23.

PMID:
17250816
14.

Oligodeoxynucleotides differentially modulate activation of TLR7 and TLR8 by imidazoquinolines.

Gorden KK, Qiu X, Battiste JJ, Wightman PP, Vasilakos JP, Alkan SS.

J Immunol. 2006 Dec 1;177(11):8164-70.

15.

Cutting edge: activation of murine TLR8 by a combination of imidazoquinoline immune response modifiers and polyT oligodeoxynucleotides.

Gorden KK, Qiu XX, Binsfeld CC, Vasilakos JP, Alkan SS.

J Immunol. 2006 Nov 15;177(10):6584-7.

16.

Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists.

Gorski KS, Waller EL, Bjornton-Severson J, Hanten JA, Riter CL, Kieper WC, Gorden KB, Miller JS, Vasilakos JP, Tomai MA, Alkan SS.

Int Immunol. 2006 Jul;18(7):1115-26. Epub 2006 May 25.

PMID:
16728430
17.

Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8.

Gorden KB, Gorski KS, Gibson SJ, Kedl RM, Kieper WC, Qiu X, Tomai MA, Alkan SS, Vasilakos JP.

J Immunol. 2005 Feb 1;174(3):1259-68.

18.

Monoclonal antibodies: the story of a discovery that revolutionized science and medicine.

Alkan SS.

Nat Rev Immunol. 2004 Feb;4(2):153-6. No abstract available.

PMID:
15040588
19.

Inhibition of T helper 2-type responses, IgE production and eosinophilia by synthetic lipopeptides.

Akdis CA, Kussebi F, Pulendran B, Akdis M, Lauener RP, Schmidt-Weber CB, Klunker S, Isitmangil G, Hansjee N, Wynn TA, Dillon S, Erb P, Baschang G, Blaser K, Alkan SS.

Eur J Immunol. 2003 Oct;33(10):2717-26.

20.

Genetic reprogramming of primary human T cells reveals functional plasticity in Th cell differentiation.

Sundrud MS, Grill SM, Ni D, Nagata K, Alkan SS, Subramaniam A, Unutmaz D.

J Immunol. 2003 Oct 1;171(7):3542-9.

22.

Glucocorticoids inhibit human antigen-specific and enhance total IgE and IgG4 production due to differential effects on T and B cells in vitro.

Akdis CA, Blesken T, Akdis M, Alkan SS, Heusser CH, Blaser K.

Eur J Immunol. 1997 Sep;27(9):2351-7.

PMID:
9341780
23.
24.

Direct measurement of cytokines (IFN-gamma, IL-4, -5, and -6) from organs after antigenic challenge.

Alkan SS, Akdiş AC, Feuerlein D, Grüninger M.

Ann N Y Acad Sci. 1996 Oct 31;796:82-90.

PMID:
8906214
25.

Epitope-specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro.

Akdis CA, Akdis M, Blesken T, Wymann D, Alkan SS, Müller U, Blaser K.

J Clin Invest. 1996 Oct 1;98(7):1676-83.

26.
27.

Cytokine immunotrapping: an assay to study the kinetics of production and consumption or degradation of human interferon-gamma.

Akdiş AC, Towbin H, Libsig P, Motz J, Alkan SS.

J Immunol Methods. 1995 Jun 9;182(2):251-61.

PMID:
7790729
28.
29.

Monoclonal anti-gamma interferon antibodies enhance experimental allergic encephalomyelitis.

Lublin FD, Knobler RL, Kalman B, Goldhaber M, Marini J, Perrault M, D'Imperio C, Joseph J, Alkan SS, Korngold R.

Autoimmunity. 1993;16(4):267-74.

PMID:
7517706
30.
31.

Three human interferon-alpha 2 subvariants disclose structural and functional differences.

von Gabain A, Lundgren E, Ohlsson M, Holmgren E, Josephsson S, Alkan SS.

Eur J Biochem. 1990 Jun 20;190(2):257-61.

32.

Tenascin, an extracellular matrix protein, exerts immunomodulatory activities.

Rüegg CR, Chiquet-Ehrismann R, Alkan SS.

Proc Natl Acad Sci U S A. 1989 Oct;86(19):7437-41.

33.

Structural characterization of antiidiotypic antibodies. Evidence that Ab2s are derived from the germline differently than Ab1s.

Meek K, Hasemann C, Pollok B, Alkan SS, Brait M, Slaoui M, Urbain J, Capra JD.

J Exp Med. 1989 Feb 1;169(2):519-33.

34.

Characterization of a monoclonal antibody against infective larvae of Brugia malayi.

Parab PB, Rajasekariah GR, Chandrashekar R, Alkan SS, Braun DG, Subrahmanyam D.

Immunology. 1988 May;64(1):169-74.

35.

Enhanced antiproliferative action of interferon targeted by bispecific monoclonal antibodies.

Alkan SS, Towbin H, Hochkeppel HK.

J Interferon Res. 1988 Feb;8(1):25-33.

PMID:
2452847
36.

Estimation of heterokaryon formation and hybridoma growth in murine and human cell fusions.

Alkan SS, Mestel F, Jiricka J, Blaser K.

Hybridoma. 1987 Aug;6(4):371-9.

PMID:
3623581
37.

Prostaglandin E2 (PGE2)-dependent suppression of interleukin alpha (IL-2) production in patients with major trauma.

Faist E, Mewes A, Baker CC, Strasser T, Alkan SS, Rieber P, Heberer G.

J Trauma. 1987 Aug;27(8):837-48.

PMID:
2956432
38.

Monoclonal antibodies to human renin: properties and applications.

Heusser CH, Bews JP, Alkan SS, Dietrich FM, Wood JM, de Gasparo M, Hofbauer KG.

Clin Exp Hypertens A. 1987;9(8-9):1259-75.

PMID:
2443280
39.

Filaria specific monoclonal antibodies for diagnosis.

Rajasekariah GR, Parab PB, Deshpande L, Alkan SS, Braun D, Subrahmanyam D.

J Commun Dis. 1986 Dec;18(4):314. No abstract available.

PMID:
3309039
40.
41.
42.

Biological activities of human recombinant interferon alpha/beta targeted by anti-Epstein-Barr virus monoclonal antibodies.

Miescher-Granger S, Hochkeppel HK, Braun DG, Alkan SS.

FEBS Lett. 1985 Jan 1;179(1):29-33.

43.

Monoclonal antibodies recognizing structural components of murine retroviruses including an FMR antigen on protein p12.

Gambke C, Senn HP, Hunsmann G, Schumann G, Moroni C, Alkan SS.

J Gen Virol. 1984 Sep;65 ( Pt 9):1507-17.

PMID:
6206201
45.

Antiviral and antiproliferative effects of interferons delivered via monoclonal antibodies.

Alkan SS, Miescher-Granger S, Braun DG, Hochkeppel HK.

J Interferon Res. 1984 Summer;4(3):355-63.

PMID:
6208296
48.
49.
50.

The cross-reactive idiotype of anti-4-azobenzenearsonate hybridoma-derived antibodies in A/J mice constitutes multiple heavy chains.

Alkan SS, Knecht R, Braun DG.

Hoppe Seylers Z Physiol Chem. 1980;361(2):191-5. No abstract available.

PMID:
6153633

Supplemental Content

Loading ...
Support Center